New diabetes clinical trial: Active You: Feasibility of a Unique Physical Activity Program to Prevent Diabetes and Heart Disease | | |
New diabetes clinical trial: DAPASALT: An Open Label, Phase IV, Mechanistic, Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function | | |
New diabetes clinical trial: Fast-Acting Insulin Aspart and Insulin Pump Settings | | |
New diabetes clinical trial: Type 1 Diabetes Meal Dosing Intervention Study | | |
New diabetes clinical trial: The Next Generation Longitudinal Birth Cohort Diabetes Study | | |
New diabetes clinical trial: Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose | | |
New diabetes clinical trial: Manipulating Narrative Presentations of Information to Encourage Good Foot Care Practice in People With and Without Diabetes Mellitus | | |
New diabetes clinical trial: Validation of a 13C Glucose Breath Test to Quantify Insulin Resistance in Type 1 Diabetes Mellitus Compared With the Euglycaemic Clamp Test | | |
New diabetes clinical trial: Physical Therapy for Diabetes Mellitus | | |
New diabetes clinical trial: Covid-19 Infection and New Onset Type 1 Diabetes | | |
New diabetes clinical trial: Efficacy and Safety of Diabetes-specific Formula in Patients With Type 2 Diabetes Mellitus | | |
New diabetes clinical trial: A Culinary-Based Intensive Lifestyle Program for Patients With Obesity and Pre-Diabetes or Diabetes | | |
New diabetes clinical trial: Neurovascular Coupling and Autonomic Neuropathy in Type 2 Diabetes | | |
New diabetes clinical trial: Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes | | Published on: November 11, 2020 at 07:00PM Condition: Type1 Diabetes Interventions: Drug: 350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule; Drug: 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule; Drug: 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule; Drug: 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule Sponsor: Immunomolecular Therapeutics, Inc. Recruiting https://clinicaltrials.gov/ct2/show/NCT04625595?term=diabetes&sfpd_d=14 November 12, 2020 at 03:24PM via ClinicalTrials.gov |
New diabetes clinical trial: Oxygenation Changes After 2-month Exercise in Sedentary Older Adults With Diabetes | | |
New diabetes clinical trial: Treatment of GLP-1 for Diabetic Bariatric Patients | | |
New diabetes clinical trial: WEB BASED EDUCATION - INDIVIDUALS WITH TYPE 2 DIABETES | | |
New diabetes clinical trial: Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus | | |
New diabetes clinical trial: A Phase 3 Randomized, Controlled Study of Oral Ladarixin in New-onset Type 1 Diabetes and a Low Residual β-cell Function | | |
Няма коментари:
Публикуване на коментар